抗体药物偶联物治疗非小细胞肺癌的研究进展和展望<sup>★</sup>

doi:10.3969/j.issn.2095-1264.2024.04.05

首页 > 过刊浏览>2024年第4期 >411-419. DOI:10.3969/j.issn.2095-1264.2024.04.05

抗体药物偶联物治疗非小细胞肺癌的研究进展和展望★
DOI:
                        10.3969/j.issn.2095-1264.2024.04.05
                    
作者:
                        
                        
                    
作者单位:1.湖南省肿瘤医院 胸部内一科，湖南 长沙，410013;2.湖南科技大学 生命科学与健康学院，湖南 湘潭，411201
作者简介:李雨凝，女，硕士研究生，研究方向：生物化学与分子生物学。
通讯作者:张乐蒙，男，博士，研究方向：肺癌的基础与临床研究。
中图分类号:R734.2
基金项目:★湖南省科技厅自然科学基金（2023JJ60039）。

Research progress and prospect of antibody-drug conjugates in the treatment of non-small cell lung cancer^★

Author:

Affiliation:

1.Department of the First Thoracic Medicine, Hunan Cancer Hospital, Changsha, 410013, Hunan, China;2.School of Life and Health Science, Hunan University of Science and Technology, Xiangtan, 411201, Hunan, China

Fund Project:

摘要

图/表

访问统计

参考文献

相似文献

引证文献

资源附件

文章评论

摘要:

抗体药物偶联物（ADC）代表一种新兴抗肿瘤治疗策略，融合了单克隆抗体的高度特异性和高细胞毒性药物的杀伤力。相对于传统化疗药物，ADC不仅能够精准识别肿瘤靶点，还能够实现药物快速传递到肿瘤细胞内，在降低全身毒副作用的同时提供更高的治疗效力。ADC已经在多种肿瘤类型中展现了出色的治疗效果，在非小细胞肺癌（NSCLC）中的应用也备受关注，本文就ADC在NSCLC治疗中的研究现状和前景进行综述。

Abstract:

Antibody-drug conjugates (ADCs) represent an emerging anticancer therapeutic strategy that combines the high specificity of monoclonal antibodies with the lethality of highly cytotoxic drugs to fully leverage the advantages of targeted therapies. Compared with traditional chemotherapy drugs, ADCs can not only accurately identify tumor targets, but also achieve rapid delivery of drugs into tumor cells, providing higher therapeutic efficacy while reducing systemic toxic side effects. ADCs have shown excellent therapeutic effect in a variety of cancer types, and its research and application in the treatment of non-small cell lung cancer has also attracted much attention. This paper reviews the research status and prospects of ADCs in the treatment of non-small cell lung cancer.